

### 1386. Lack of Clinically Relevant Effect of Bictegravir (BIC, B) on Metformin (MET) Pharmacokinetics (PK) and Pharmacodynamics (PD)

Joseph Custodio, PhD<sup>1</sup>; Steve West, MSPH<sup>2</sup>; Amanda Yu, BSc<sup>3</sup>; Hal Martin, MD, MPH<sup>4</sup>; Hiba Graham, PharmD<sup>4</sup>; Erin Quirk, MD<sup>4</sup> and Brian Kearney, PharmD<sup>5</sup>; <sup>1</sup>Gilead Sciences, Inc., Foster City, California, <sup>2</sup>Biostatistics, Gilead Science, Foster City, California, <sup>3</sup>Clinical Operation, Gilead Science, Foster City, California, <sup>4</sup>Gilead Sciences, Foster City, California, <sup>5</sup>Clinical Pharmacology, Gilead Science, Foster City, California

Session: 156. HIV: Antiretroviral Therapy

Friday, October 6, 2017: 12:30 PM

**Background.** BIC is a novel integrase inhibitor coformulated with emtricitabine (F) and tenofovir alafenamide (TAF) for treatment of HIV. MET is first-line therapy in diabetic HIV patients. *In vitro*, BIC inhibits renal transporters OCT2 and MATE1, which affect MET disposition. This study evaluated the effect of BIC on the PK and PD of MET following coadministration with the B/F/TAF.

**Methods.** This was a Phase 1, blinded, placebo-controlled, crossover study in 32 healthy subjects randomized 1:1 to either B/F/TAF or placebo QD for 9 days followed by a 3-day washout. Following 4 days of B/F/TAF or placebo, subjects received 850 mg MET at 12 hours postdose of B/F/TAF or placebo, and 500 mg BID for 4 additional days. Plasma and urine PK of MET were assessed on the last treatment day (Days 9 and 21 for B/F/TAF or placebo). Oral glucose tolerance test was performed before (Days 5 and 17) and after MET (Days 9 and 21). MET PD endpoints including plasma glucose, active Glucagon-Like Peptide 1 (GLP-1) and lactate were assessed after glucose intake. Geometric mean ratios (GMR) and 90% confidence intervals (CIs) for MET PK were calculated for B/F/TAF vs. placebo. Comparisons of PD responses within treatments (before vs. after MET) and comparisons between treatments (B/F/TAF vs. placebo) were done via nonparametric Wilcoxon signed-rank test ( $P > 0.05$  denotes non-significance).

**Results.** MET plasma AUC<sub>0-∞</sub> was increased 39% (%GMR [90% CI]: 139 [131, 148]) with B/F/TAF vs. placebo, with no change in median plasma t<sub>1/2</sub> (B/F/TAF: 6.4 hours; placebo: 7.1 hours). MET renal clearance decreased 31% with B/F/TAF vs. placebo. Following MET administration, statistically significant reduction of plasma glucose, and increase of plasma active GLP-1 and lactate levels relative to baseline were observed ( $P < 0.001$ ) confirming their utility as PD endpoints. Importantly, PD responses were not statistically different when MET was administered with B/F/TAF vs. placebo ( $p > 0.05$ ).

**Conclusion.** Inhibition of renal transporters OCT2/MATE1 by BIC led to a modest increase of MET plasma exposure upon coadministration with B/F/TAF; however, the PD characteristics of MET were not significantly affected by B/F/TAF relative to placebo. Based on these findings, prospective dose adjustment/restriction of MET is not required upon coadministration with B/F/TAF.

**Disclosures.** J. Custodio, Gilead Sciences: Employee and Shareholder, Salary; S. West, Gilead Sciences: Employee and Shareholder, Salary; A. Yu, Gilead Science: Employee, Salary; H. Martin, Gilead Sciences: Employee, Salary; H. Graham, Gilead Sciences: Employee and Shareholder, Salary; E. Quirk, Gilead: Employee and Shareholder, Salary; B. Kearney, Gilead: Employee and Shareholder, Salary

### 1387. Impact of Tablet Burden and Antiretroviral Therapy (ART) Choice on Virologic Outcomes in Treatment Naive HIV+ Individuals Attending an Inner City Clinic

Norman Markowitz, MD<sup>1</sup>; Beni Tidwell, BS<sup>2</sup>; Lois Lamerato, PhD<sup>1</sup>; Susan Zelt, DrPH, MBA<sup>3</sup>; Ronald D'Amico, DO, MS<sup>3</sup> and Kathy Schulman, MA<sup>2</sup>; <sup>1</sup>Henry Ford Health System, Detroit, Michigan, <sup>2</sup>Outcomes Research Solutions, Inc., Waltham, Massachusetts, <sup>3</sup>ViiV Healthcare, Research Triangle Park, North Carolina

Session: 156. HIV: Antiretroviral Therapy

Friday, October 6, 2017: 12:30 PM

**Background.** The durability and effectiveness of single tablet regimens (STR) in treating ART naïve patients in real world, inner city settings, has not been well established.

**Methods.** Data was abstracted from administrative/medical records at Henry Ford Health System, serving metropolitan Detroit, for HIV+ patients initiating ART (1/1/2007–9/30/2015), who were enrolled in the Health Alliance Plan (HAP) or had ≥1 clinician contact per year and ≥1 viral load (VL)/CD4 test result ≤90 days prior to ART initiation. Patients were followed from initiation to first of: change in ART, death, HAP disenrollment, study end (03/31/2016), or lost to follow-up. Cox regression estimated impact of tablet burden on ART regimen duration, achievement of viral suppression (VS) and viral failure—(VF) failure to suppress plasma HIV RNA to <50 copies/mL or rebound after VS.

**Results.** Among 390 eligible patients, 79% were male, 74% African-American. Median (IQR) age was 37 years (27–47), 49% MSM and 22% presented with AIDS. The majority (65%) initiated on an STR; 35% on multiple tablet regimens (MTR). The majority of STR initiators (63%) began with EFV/FTC/TDF; 24% with EVG/c/FTC/TDF; and 8% with DTG/ABC/3TC. The most frequent MTR were DRV+RTV+TDF/FTC (26%) and ATV+RTV+TDF/FTC (20%). Median (IQR) log<sub>10</sub> VL at baseline was 4.8 (4.3–5.2) in STR; 4.8 (4.4–5.4) in MTR cohorts. Median CD4 cells/μL (IQR) was 277 (115–407) in STR; 231 (37–371) in MTR.

VL suppression occurred in 81% (85% STR, 74% MTR,  $P < 0.01$ ) of patients and in 91% of INSTI regimens (91% STR, 90% MTR,  $P = 0.757$ ). VF occurred in 19% (15% STR, 25% MTR,  $P = 0.015$ ) and in 10% of INSTI regimens (9% STR, 13% MTR,  $P = 0.459$ ). Resistance occurred in 15% of VF patients, predominantly with NNRTI

mutations. A total of 22% of STR and 60% of MTR initiators experienced a change in their initial ART regimen ( $P < 0.0001$ ). Cox model results suggest STR initiators were 59% less likely to experience regimen change ( $P < 0.0001$ ), 46% less likely to experience VF ( $P < 0.05$ ) and 30% more likely to achieve viral suppression ( $P < 0.05$ ) compared with MTR initiators.

**Conclusion.** Inner city, HIV treatment naïve patients, initiating ART with a STR are significantly more likely to achieve viral suppression and less likely to experience a change in ART regimen.

**Disclosures.** B. Tidwell, ViiV Healthcare: Research Contractor, Research support; L. Lamerato, ViiV Healthcare: Collaborator, Research support; S. Zelt, ViiV Healthcare: Employee and Shareholder, Salary and Stock; R. D'Amico, ViiV Healthcare: Employee and Shareholder, Salary and Stock; K. Schulman, ViiV Healthcare: Research Contractor, Research support

### 1388. Pharmacokinetics of Cabotegravir in Subjects with Moderate Hepatic Impairment

Jafar Sadik Shaik, PhD<sup>1</sup>; Susan Ford, PharmD<sup>2</sup>; Yu Lou, MS<sup>2</sup>; Zhiping Zhang, PhD<sup>2</sup>; Kalpana Bakshi, MS<sup>3</sup>; Allan Tenorio, MD<sup>4</sup>; Christine Trezza, PharmD<sup>4</sup>; William Spreen, PharmD<sup>4</sup> and Parul Patel, PharmD<sup>4</sup>; <sup>1</sup>GlaxoSmithKline, Upper Merion, Pennsylvania, <sup>2</sup>PAREXEL International, Durham, North Carolina, <sup>3</sup>GlaxoSmithKline, Collegeville, Pennsylvania, <sup>4</sup>ViiV Healthcare, Research Triangle Park, North Carolina

Session: 156. HIV: Antiretroviral Therapy

Friday, October 6, 2017: 12:30 PM

**Background.** Cabotegravir (CAB) is an integrase inhibitor in phase 3 clinical trials for the treatment and prevention of HIV. CAB undergoes hepatic metabolism primarily via UGT1A1; thus hepatic impairment has the potential to affect CAB exposure.

**Methods.** This was a multi-center, single-dose, open-label, parallel group study to evaluate the effect of moderate hepatic impairment on the pharmacokinetics (PK) and safety of CAB. Adults with moderate hepatic impairment as determined by Child-Pugh classification score of 7–9 ( $n = 8$ ) and matched healthy control subjects ( $n = 8$ ) were enrolled. Control subjects were matched for gender, age ( $\pm 10$  years), and body mass index (BMI) ( $\pm 25\%$ ). Subjects received oral CAB 30 mg as a single dose in the fasted state followed by serial PK sampling for 168 hours. CAB unbound concentrations at 2 and 24 hours after dosing were determined by equilibrium dialysis. Non-compartmental PK analysis was performed; geometric least squares (GLS) mean ratios (hepatic impaired group/control group) and 90% confidence intervals (CI) were generated.

**Results.** Sixteen subjects completed study; 12 (75%) male, mean age 59 years (range: 51–67), mean BMI 29 kg/m<sup>2</sup> (range: 21–37), and total Child Pugh score in range of 7–9. CAB PK parameters were similar between subjects with moderate hepatic impairment and matched healthy subjects. The GLS mean ratios (90% CI) for AUC(0–∞), C<sub>max</sub>, C<sub>24</sub>, CL/F, and t<sub>1/2</sub> were 0.73 (0.50, 1.06), 0.69 (0.51, 0.93), 0.73 (0.53, 1.02), 1.38 (0.95, 2.01), and 0.82 (0.65, 1.04), respectively. Although highly protein bound, the unbound fraction of CAB was increased in subjects with moderate hepatic impairment relative to healthy subjects with GLS mean ratio (90%CI) of 2.14 (1.57, 2.90) at 2 hours post dose and 1.90 (1.14, 3.18) at 24 hours post dose; this was associated with lower serum albumin concentrations and was not considered clinically significant. All adverse events (AE) were reported as mild (Grade 1) to moderate (Grade 2) in severity and no serious AEs were reported.

**Conclusion.** Plasma exposures of CAB in subjects with moderate hepatic impairment were similar to those in healthy subjects. No dose adjustment of CAB is required for subjects with mild to moderate hepatic impairment.

**Disclosures.** J. S. Shaik, GlaxoSmithKline: Employee and Shareholder, Salary; S. Ford, PAREXEL International: Employee, Salary; Y. Lou, PAREXEL International: Employee, Salary; Z. Zhang, PAREXEL International: Employee, Salary; K. Bakshi, GlaxoSmithKline: Employee and Shareholder, Salary; A. Tenorio, ViiV Healthcare: Employee and Shareholder, Salary; C. Trezza, ViiV Healthcare: Employee and Shareholder, Salary; W. Spreen, ViiV Healthcare: Employee and Shareholder, Salary; P. Patel, ViiV Healthcare: Employee and Shareholder, Salary

### 1389. Pharmacokinetics of Cabotegravir in Subjects with Severe Renal Impairment

Ridhi Parasrampur, PhD<sup>1</sup>; Susan Ford, PharmD<sup>2</sup>; Yu Lou, MS<sup>2</sup>; Caifeng Fu, MS<sup>3</sup>; Kalpana Bakshi, MS<sup>3</sup>; Allan Tenorio, MD<sup>4</sup>; Christine Trezza, PharmD<sup>4</sup>; William Spreen, PharmD<sup>4</sup> and Parul Patel, PharmD<sup>4</sup>; <sup>1</sup>GlaxoSmithKline, Upper Merion, PA, <sup>2</sup>PAREXEL International, Durham, North Carolina, <sup>3</sup>GlaxoSmithKline, Collegeville, Pennsylvania, <sup>4</sup>ViiV Healthcare, Research Triangle Park, North Carolina

Session: 156. HIV: Antiretroviral Therapy

Friday, October 6, 2017: 12:30 PM

**Background.** Cabotegravir (CAB) is an integrase inhibitor in phase 3 clinical trials for the treatment and prevention of HIV. CAB undergoes glucuronidation via UGT1A1 with <1% renal elimination of unchanged CAB. Renal impairment may affect PK of drugs that are primarily metabolized or secreted in bile; thus impact of renal impairment on CAB pharmacokinetics was evaluated.

**Methods.** This was a multi-center, single-dose study of oral CAB 30mg administered to subjects with severe renal impairment (creatinine clearance [CL<sub>Cr</sub>] <30 mL/minute; not on renal replacement therapy) and to healthy controls (CL<sub>Cr</sub> ≥90 mL/minute) matched for gender, age ( $\pm 10$  years), and body mass index (BMI) ( $\pm 25\%$ ) (8 per